CALGARY, ALBERTA--(MARKET WIRE)--Sep 12, 2007 -- Resverlogix Corp. (“Resverlogix”) (Toronto:RVX.TO - News) is pleased to announce today that a portion of the Company’s key preclinical data has been published in Current Opinion in Investigational Drugs. The article titled “Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis” is an article that details the many approaches to increasing ApoA-l/HDL.
